LEXX Lexaria Bioscience Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LEXX

Price (delayed)

$0.669

Market cap

$16.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.47

Enterprise value

$11.55M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's ...

Highlights
The debt has declined by 24% year-on-year and by 7% since the previous quarter
The EPS rose by 20% year-on-year and by 16% since the previous quarter
Lexaria Bioscience's equity has increased by 34% from the previous quarter but it has decreased by 8% YoY
The gross profit has contracted by 30% YoY and by 30% from the previous quarter
LEXX's revenue is down by 30% year-on-year and by 30% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lexariabioscience.com
Peers: AMRN INVA TVRD CRBP

Key stats

What are the main financial stats of LEXX

LEXX stock price

How has the Lexaria Bioscience stock price performed over time
Intraday
7.97%
1 week
7.89%
1 month
-0.37%
1 year
-30.38%
YTD
8.43%
QTD
-14.23%

Financial performance

How have Lexaria Bioscience's revenue and profit performed over time
Revenue
$368,000
Gross profit
$368,000
Operating income
-$9.46M
Net income
-$9.53M
Gross margin
100%
Net margin
-2,589.7%
The net margin has declined by 45% year-on-year and by 25% since the previous quarter
The operating margin has declined by 44% year-on-year and by 25% since the previous quarter
The gross profit has contracted by 30% YoY and by 30% from the previous quarter
LEXX's revenue is down by 30% year-on-year and by 30% since the previous quarter

Price vs fundamentals

How does LEXX's price correlate with its fundamentals

Growth

What is Lexaria Bioscience's growth rate over time

Valuation

What is Lexaria Bioscience stock price valuation
P/E
N/A
P/B
2.52
P/S
44.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.38
The EPS rose by 20% year-on-year and by 16% since the previous quarter
LEXX's P/B is 43% below its last 4 quarters average of 4.1 and 33% below its 5-year quarterly average of 3.5
Lexaria Bioscience's equity has increased by 34% from the previous quarter but it has decreased by 8% YoY
LEXX's revenue is down by 30% year-on-year and by 30% since the previous quarter
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 58.5 but 14% more than its last 4 quarters average of 36.0

Efficiency

How efficient is Lexaria Bioscience business performance
Lexaria Bioscience's ROE has plunged by 78% YoY but it has increased by 9% from the previous quarter
Lexaria Bioscience's ROA has plunged by 62% YoY but it has increased by 3.4% from the previous quarter
The company's return on invested capital has shrunk by 54% YoY but it has surged by 53% QoQ
The return on sales has declined by 45% year-on-year and by 25% since the previous quarter

Dividends

What is LEXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LEXX.

Financial health

How did Lexaria Bioscience financials performed over time
The total liabilities has dropped by 86% year-on-year and by 82% since the previous quarter
The total assets has contracted by 25% YoY but it has grown by 7% from the previous quarter
The debt is 99% smaller than the equity
LEXX's debt to equity has shrunk by 50% QoQ and by 50% YoY
Lexaria Bioscience's equity has increased by 34% from the previous quarter but it has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.